1 Outcome Reporting bias in Exercise Oncology trials (OREO): a cross-sectional study

- 2 Benjamin Singh¹, Ciaran M Fairman², Jesper F Christensen^{3,4}, Kate A Bolam⁵, Rosie
- 3 Twomey⁶, David Nunan⁷, and Ian M Lahart⁸.
- 4 ¹ Greenslopes Private Hospital, Brisbane, Australia
- ² Exercise Science, Arnold School of Public Health, University of South Carolina, South
 Carolina, USA
- ³ Centre for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark
- 8 ⁴ Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences,
- 9 University of Southern Denmark, Denmark
- ⁵ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm,
 Sweden
- ⁶ Cumming School of Medicine, University of Calgary, Calgary, Canada
- ¹³ ⁷Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- ⁸ Sport and Physical Activity Research Centre, Faculty of Education, Health, and Wellbeing,
 University of Wolverhampton, Wolverhampton, UK
- 16 Corresponding author: Ian M Lahart, <u>i.lahart@wlv.ac.uk</u>
- 17

18 Abstract:

- 19 Background: Despite evidence of selective outcome reporting across multiple disciplines, this
- 20 has not yet been assessed in trials studying the effects of exercise in people with cancer.
- 21 Therefore, the purpose of our study was to explore prospectively registered randomised
- 22 controlled trials (RCTs) in exercise oncology for evidence of selective outcome reporting.
- Methods: Eligible trials were RCTs that 1) investigated the effects of at least partially supervised exercise interventions in people with cancer; 2) were preregistered (i.e. registered before the first patient was recruited) on a clinical trials registry; and 3) reported results in a peer-reviewed published manuscript. We searched the PubMed database from the year of **increption**preprint Septembers 2020 at the identified beer exercise should be proved by the RCT in a database from the year of

registries. Eligible trial registrations and linked published manuscripts were compared to identify the proportion of sufficiently preregistered outcomes reported correctly in the manuscripts, and cases of outcome omission, switching, and silently introduction of non- novel outcomes.

Results: We identified 31 eligible RCTs and 46 that were ineligible due to retrospective 32 registration. Of the 405 total prespecified outcomes across the 31 eligible trials, only 6.2% were 33 34 preregistered complete methodological detail. Only 16% (n=148/929) of outcomes reported in published results manuscripts were linked with sufficiently preregistered outcomes without 35 outcome switching. We found 85 total cases of outcome switching. A high proportion (41%) 36 37 of preregistered outcomes were omitted from the published results manuscripts, and many 38 published outcomes (n=394; 42.4%) were novel outcomes that had been silently introduced (median, min-max=10, 0-50 per trial). We found no examples of preregistered efficacy 39 40 outcomes that were measured, assessed, and analysed as planned.

Conclusions: We found evidence suggestive of widespread selective outcome reporting and
non-reporting bias (outcome switching, omitted preregistered outcomes, and silently
introduced novel outcomes). The existence of such reporting discrepancies has implications for
the integrity and credibility of RCTs in exercise oncology.

45

Preregistered protocol: <u>https://osf.io/dtkar/</u> (posted: November 19, 2019)

46

47

48

49

50 "OF COOKING. This is an art of various forms, the object of which is to give to ordinary
51 observations the appearance and character of those of the highest degree of accuracy. One of
52 its numerous processes is to make multitudes of observations, and out of these to select those
53 only which agree, or very nearly agree. If a hundred observations are made, the cook must be
54 very unlucky if he cannot pick out fifteen or twenty which will do for serving up."

55 Charles Babbage, Reflections on the decline of science in England, and on some of its causes,

56

29th April 1830 (1).

57 INTRODUCTION

Exercise oncology-the study of exercise in people living with and beyond cancer-has 58 witnessed an exponential growth in research over the last 30 years. Hundreds of randomized 59 controlled trials (RCTs) examining the feasibility, safety, efficacy, or effectiveness of exercise 60 61 interventions before, during, and after active oncology treatment across different cancer types 62 have contributed to an ever-growing multitude of systematic reviews and meta-analyses, which in turn have been synthesized in umbrella reviews (2,3). Such evidence now underpins clinical 63 exercise guideline recommendations, including specific exercise prescriptions for some cancer-64 related health outcomes (4,5) and appeals for exercise to be viewed as standard practice in 65 oncology (6,7). 66

67 RCTs are considered the optimal design to assess whether health interventions offer a benefit or cause harm, and therefore, provide important evidence for clinical decision-making 68 (8). However, reporting biases such as selective (non-) reporting of outcomes (see Box 1 for 69 definitions) threaten the validity of RCTs, and therefore the reviews and guidelines they inform. 70 The prevalence and impact of these outcome reporting biases in the wider published biomedical 71 literature has been well studied and highlights an abundance of potential false positive findings, 72 interventions with likely overestimated benefits and underestimated harms, and meta-analyses 73 overwhelmingly in favour of studied interventions (9–14). 74

75

Box 1. Definitions of reporting biases [definitions taken from: (13,15)]

Type of bias	Definition		
Reporting bias	Reporting bias occurs when the reporting of research findings may depend on the nature (e.g., statistical significance) and direction of the results. Examples of reporting bias include publication bias, language bias, citation bias, and selective (non-) reporting bias.		
Publication bias	The (non-)publication of research findings, depending on the nature (e.g., statistical significance) and direction of the results.		
Selective (non-) reporting bias	The selective reporting of a subset of outcomes or analyses, but not others, depending on the nature (e.g., the size of the p-value or effect size) and direction of the results.		
	Three types of selective reporting bias :		
	 Selective outcome (non-)reporting bias: the selective reporting or non-reporting of some of the set of study outcomes, when not all analysed outcomes are reported. 		
	 The selective reporting of a specific outcome—for example, when an outcome is measured and analysed at several time points but not all results are reported. 		
	 3) Incomplete reporting of a specific outcome—for example, when the <i>p</i>-value from a statistical test for an outcome is reported but no descriptive statistics are given. 		

77

Although selective reporting bias, or 'cooking' as Charles Babbage dubbed it in 1830, 78 79 is a long-standing problem in science publication, direct evidence of its existence has only surfaced more recently. In a landmark paper in 2004, Chan and colleagues (10) discovered that 80 62% of RCTs approved by the Scientific-Ethical Committees for Copenhagen and 81 82 Frederiksberg, Denmark, had at least one primary outcome that was switched for a nonsecondary outcome (i.e. outcome switching), silently introduced, or omitted when they 83 84 compared published trial manuscripts with their accompanying protocols. The authors (10) concluded that to "ensure transparency, planned trials should be registered and protocols should 85 be made publicly available prior to trial completion" (pp. 2457). 86

87 Several initiatives now exist to explicitly address the negative impacts of selective 88 reporting bias. For over a decade, an international standard for clinical trials is prospective

89 registration in a public database before recruitment of the first participant (16–18). This is mandated by the Declaration of Helsinki (17), endorsed by the World Health Organization 90 (WHO) (19), and a requirement for publication of trial findings in member journals of the 91 International Committee of Medical Journal Editors (ICMJE) (18). Clinical trial registration 92 aims to track all initiated trials, identify unpublished trials, achieve transparency in trial 93 reporting (a fundamental tenet of science), and make key information about the objectives and 94 95 design of a trial publicly available (12,20,21). A prospective registration also allows for the distinction between confirmatory outcomes and those which are exploratory (22,23). Although 96 97 trial registries have served as an audit trail for documenting discrepancies between registrations and trial publications, they do not appear to have acted as a deterrent to selective reporting 98 biases (12,24–26). 99

100 In 2019, Goldacre and colleagues (26) provided strong evidence that selective outcome 101 reporting is still a major concern even in those trials published in so-called prestige journals. The authors (26) prospectively assessed outcome reporting in all newly published trials in five 102 103 of the highest impact medical journals over a 6-week period, and revealed that 87% of trials had discrepancies serious enough to warrant a correction letter, and five undeclared outcomes 104 105 were on average added per trial. Similar evidence of reporting discrepancies has been observed 106 across many disciplines (24), including psychology (25), cognitive science (27), cystic fibrosis (28), anaesthesiology (29), drug trials (30,31), and oncology (32,33). 107

Exercise oncology shares with these disciplines many of the features that can propagate selective (non-) reporting bias, such as a preponderance of studies with positive or favourable results, non-cooperative group trials, assessment of a vast array of outcomes from a multitude of measurement tools, large researcher degrees of freedom when choosing between outcome and analysis options, and high pressures to publish (27,34–36). Given these similarities, it

seems unreasonable to believe that exercise oncology research is immune to the problems thathave contributed to a 'credibility crisis' in other disciplines (37).

A recent umbrella review reported that the effect size estimates are typically small-115 moderate, and the certainty of the evidence is typically graded as low or moderate across meta-116 analyses of exercise oncology RCTs (3). Consequently, many effects within these meta-117 analyses may be vulnerable to selective (non-) reporting bias, which could change the direction, 118 size, and certainty of pooled effect estimates. The existence of selective (non-) reporting in 119 exercise oncology trials risks undermining exercise-based clinical guidelines and calls to 120 include exercise in the standard care of patients with cancer (6). To date, however, selective 121 122 (non-) reporting biases have not been assessed in RCTs of exercise interventions for people 123 diagnosed with cancer. Therefore, the overall purpose of this study is to evaluate selective (non-) reporting in prospectively registered RCTs in the field of exercise oncology. 124

125

126 METHOD

127 Our study protocol was preregistered on November 19, 2019 and can be accessed here:
 128 <u>https://osf.io/dtkar/</u>.

129

130 Search and trial eligibility

Eligible trials: 1) were longitudinal RCTs investigating the efficacy or effectiveness of at least partially supervised exercise interventions on health-related outcomes in people diagnosed with cancer; 2) were preregistered on either ClinicalTrials.gov, the International Standard Randomised Controlled Trials Number (ISRCTN) registry via the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), the European Union (EU) Clinical Trials Register, the Australian and New Zealand Clinical Trials Registry (ANZCTR), Netherlands Trial Registry (NTR), the Chinese Clinical Trial Registry (ChiCTR),

or the UMIN Clinical Trials Registry (UMIN-CTR); and 3) reported their findings in at least
one full-text article in a peer-reviewed journal. We did not exclude trials based on cancer type
or stage, or treatment status (e.g., during or following adjuvant therapy, pre- or post-surgery).

In line with the ICMJE's definition of a clinical trial (18), we defined an exercise 141 oncology RCT as a research project that prospectively and randomly assigned individuals 142 diagnosed with cancer to intervention or comparison groups to study the cause-and-effect 143 relationship between an exercise intervention and a health outcome. We adopted the following 144 definition of exercise: "a potential disruption to homeostasis by muscle activity that is either 145 exclusively, or in combination, concentric, eccentric or isometric muscle contractions" (38). 146 147 We included both efficacy studies that examined the benefits or harms of an exercise 148 intervention under controlled conditions and effectiveness or pragmatic trials that investigated exercise interventions under conditions that were closer to real-world practice (39), if they 149 150 involved some level of face-to-face supervision. We excluded behaviour-based trials (i.e. studies that focused primarily on increasing physical activity). Exercise interventions that 151 involved a behaviour change component, however, were included if some level of face-to-face 152 exercise supervision was involved. Trials that evaluated drug, dietary, supplement, or 153 alternative interventions in combination with exercise were eligible only if the effects of 154 155 exercise could be isolated (i.e. if a comparison group also receives the drug or supplement without exercise; e.g., an exercise plus drug arm vs. a drug only arm). 156

We defined a preregistered trial as a trial that was prospectively registered (i.e. the trial was registered on or before the stated study start date or onset of patient enrolment) on any of the clinical trial registries listed above (we accepted trials that had a start date the same month as they were registered, if the day of the month was not reported) (40). We excluded, but made note of, retrospectively registered trials (i.e. those that were registered during or after the completion of the study), because they may have been registered after an interim or final data

analyses, allowing for selective registration of certain outcomes dependent on the outcome
direction or statistical significance. Additionally, papers linked to eligible trials that reported
only the results of cross-sectional analyses were excluded if they did not compare the effects
of an eligible exercise intervention on outcomes versus comparison groups.

167

168 Outcomes

169 Primary outcome:

170 The proportion of sufficiently preregistered primary and secondary outcomes reported171 correctly in published manuscripts.

• Outcome preregistration was considered 'sufficiently' reported when the preregistered outcome indicated the outcome score (e.g., the FACT-general total score is an outcome score used as a measure of quality of life) and not only the outcome domain (e.g., registering "quality of life" alone was considered insufficient).

'Correctly' reported outcomes were outcomes that were preregistered primary outcomes reported in publications as a primary outcome or preregistered secondary outcomes reported in publications as secondary outcomes, or in cases where the authors declared and provided a justification for discrepancies between the preregistration and published manuscript.

182 Secondary outcomes:

The proportion of (both sufficiently preregistered and domain only) primary outcomes
 omitted or reported as a secondary outcome in the published manuscripts (i.e. outcome
 switching).

186	2.	The proportion of (both sufficiently preregistered and domain only) secondary
187		outcomes omitted or reported as primary outcomes in the published manuscripts (i.e.
188		outcome switching).

- 189 3. The total number of instances of outcome switching in preregistered primary and190 secondary outcomes.
- 4. The number of undeclared and non-preregistered (novel) outcomes added to publishedmanuscripts (i.e. silently introduced).
- 5. The proportion of sufficiently preregistered outcomes with descriptions in published
 manuscripts consistent with their preregistered descriptions (i.e. method of assessment,
 outcome score, assessment timepoints, and statistical analysis plan matches the
 description in the published manuscripts).

197

198 Search of trials

We undertook a PubMed database search to identify all potentially eligible exercise 199 RCTs involving patients diagnosed with cancer using registry-specific search terms (Secondary 200 Source IDs) for the following registries: ClinicalTrials.gov, ISRCTN registry, the WHO 201 ICTRP, the EU Clinical Trials Register, ANZCTR, NTR, ChiCTR, and the UMIN-CTR. 202 Details of the PubMed search strategy are presented in Supplementary Table 1. We searched 203 for trials registered from the year of database inception to November 2019 (and updated 204 205 September 2020). Of note, the earliest trial registry started in 2000 [ClinicalTrials.gov, (41)], and registries were seldom used prior to the 2004 ICMJE statement requiring trial registration 206 (40).207

One investigator (IML) undertook the registry searches and uploaded all records identified during the search to Rayyan systematic review software [Qatar Computing Research Institute (Data Analytics)]. We searched the WHO ICTRP registry (no Secondary Source ID

was available for this registry) separately using a title and keyword search (Supplementary
Table 1) and exported the search results into Microsoft ExcelTM. Two investigators (BS and
CMF) independently screened all records detected during the registry search (in Rayyan and
Microsoft Excel) to identify potentially eligible trials applying the eligibility criteria described
above. A third investigator (IML) resolved any discrepancies.

We identified published manuscripts linked to each trial via a PubMed and Google 216 217 Scholar search (November 2019, and updated in September 2020) using the trial registry code (e.g., NCT number), and a search of publication lists on the trial registrations (e.g., 218 Clinicaltrials.gov lists publications automatically indexed to a study by NCT Number). We 219 220 also searched for a prospectively published version of a protocol for each trial that was dated before the trial start date (i.e. preregistered). Where a prospective trial registration was 221 accompanied by a preregistered published protocol paper, the trial registration was used an a 222 223 *priori*. If the protocol did not sufficiently define the prespecified outcomes, the registry entry was used instead, and vice versa [for only three trials, (42–44)], additional information was 224 taken from the published protocol due to a lack of detail in the registry entries). We also 225 accessed supplementary material linked to a published article to extract the required data. 226

227

228 Data extraction and coding

Five investigators (BS, CMF, IML, DN, and KAB) extracted all relevant information from the eligible studies and recorded this on specifically designed data forms (<u>https://bit.ly/3qFkcro</u>). From the registration entry of each trial, the following information was extracted: registration date, trial start date, current status, onset of participant enrolment, primary completion date (i.e. date of final collection of data for the primary outcome), nature and number of the reported outcome measures with their methods and time frame for data collection, timepoints at which the outcomes are assessed, planned statistical analysis (including power analysis), and

registered changes in outcome measures (or trial procedures) with corresponding dates. Next, 236 across all eligible publications and associated supplementary materials, we (BS, CMF, IML, 237 and KAB) extracted patient, cancer (e.g., sample size details, patients' gender, cancer type, and 238 treatment status), trial, and intervention characteristics (trial duration, condition numbers and 239 types, and exercise type), matched the reporting of outcomes prespecified in the registries to 240 241 that of the publications, and noted the *p*-values, effect sizes, and descriptive statistics [e.g., 242 mean differences between groups with 95% confidence intervals (CIs)] of all outcomes reported. 243




Figure 1. Example of the 5 Levels of Specification in Reporting Outcome Measures. The

boxes in green provide an example of sufficient reporting at each level.

247

244

248 Assessing the completeness of preregistrations

- 249 We assessed the completeness of preregistrations using a modified version of Zarin et
- al.'s (45) "four levels of specification in reporting outcome measures" method. Specifically,

we established whether authors preregistered the following: 1) outcome domain (i.e. broad categories of outcomes that can be represented by multiple outcome scores measured via different instruments or scales, e.g., quality of life); 2) outcome measure method (e.g., FACT-General questionnaire); 3) outcome assessment timepoints (e.g., baseline and post-intervention at 12 weeks); 4) outcome score (i.e. the score that would be entered into a subsequent statistical analysis, e.g., FACT-General total score); and 5) analysis of outcome score (e.g., ANCOVA on post-intervention means adjusting for baseline values) (Figure 1).

If trial authors prespecified only the outcome domain (level 1) but not an outcome score 258 (level 4), we referred to this as an 'outcome domain-only' preregistration. Researchers 259 260 registering their trials on clinical trials registries are directed to provide complete definitions 261 of all outcome measures (scores), under the principle that the information provided should be sufficient to allow other researchers to use the same outcomes. Specifically, Clinicaltrials.gov 262 263 states that researchers should: 1) state the name of the specific primary or secondary outcome measure (e.g., a descriptive name of the scale, physiological parameter, or questionnaire); 2) 264 provide a description of the metric for how the collected measurement data will be aggregated 265 (e.g., mean change from baseline); and 3) report the timepoint(s) at which the measurement is 266 assessed for the specific metric used. The two examples given for appropriate outcome measure 267 268 descriptions are: "Number of Participants with Treatment-related Adverse Events as Assessed by CTCAE v4.0," and "Mean Change from Baseline in Pain Scores on the Visual Analog Scale 269 at 6 Weeks" (46,47). Similarly, the WHO requires researchers to provide the "name of the 270 271 outcome, the metric or method of measurement used (be as specific as possible), and the timepoint(s) of interest" (16). 272

Although a pre-planned statistical analysis is considered an essential component of preregistration (22,23,48), clinical trial registries or the ICMJE (40) do not explicitly require trialists to register their statistical analysis. Therefore, we assessed the completeness of

preregistration that would meet 1) WHO/ICMJE standards (i.e. outcome method, score, and
assessment timepoints) and 2) the standards that would allow readers to distinguish between
analyses planned *a priori* and those planned *post hoc* (i.e. outcome method, score, assessment
timepoints, and statistical analysis).

280

281 Analysis of outcomes reported

282 The decision tree in Figure 2 illustrates how we handled each outcome identified in a prospective registration. First, we distinguished between outcomes prespecified with an 283 outcome score (we defined these as "sufficiently preregistered outcomes") and those domain-284 only registered. For preregistered domain-only outcomes, we checked the paper for related-285 outcomes (e.g., FACIT-Fatigue total score reported as an outcome in a publication would be 286 related to a domain-only entry of 'Fatigue' in the linked registry). This represents a necessary 287 deviation from our planned approach for the current study. Our intended and more conservative 288 approach of including only outcomes with prespecified measurement methods, outcome scores, 289 assessment timepoints, and descriptions of how the metrics were calculated and used, would 290 291 have yielded too few outcomes for our analysis. In addition, this deviation allowed us to account for all outcomes reported in eligible trial publications. For full transparency, we have 292 293 provided decisions made regarding outcomes in Supplementary Table 2.

For outcomes prespecified with outcome scores in the registry entries, we first recorded whether they were reported in or omitted from trial publications (Figure 2). In the case of the omitted outcomes, we also noted whether they were prespecified as primary or secondary outcomes. Sufficiently preregistered outcomes reported in eligible publications, were then checked to determine whether outcome switching had occurred. In line with the CONSORT guidelines (49), if researchers made any changes to trial outcomes after the trial commenced

- 300 but clearly reported these changes in the published manuscript, we considered these outcomes
- to be correctly reported (because the reason for outcome switching was declared and likely to
- 302 be justified). We reported these cases where present.




Figure 2. Outcome reporting categorisation decision tree

305

303

For those primary outcomes preregistered with scores, we assessed whether 306 307 discrepancies—outcome switching and novel outcomes silently introduced as primary outcomes—favoured 'statistically significant' results. A discrepancy was considered to favour 308 statistically significant results when: 1) a non-statistically significant (p-value > 0.05, or above 309 an *a priori* threshold stated by the authors, or a confidence interval that crossed zero) 310 311 preregistered primary outcome was demoted to a secondary or non-primary outcome in the published manuscript; 2) a statistically significant (*p*-value <0.05 or below an *a priori* threshold 312 313 stated by the authors, or a confidence interval that did not cross zero) preregistered secondary outcome promoted to a primary outcome in the published manuscript; and 3) newly introduced 314

non-preregistered statistically significant primary outcomes in the published article. We selected the results of between group comparisons as *a priori* but in cases of within-group comparisons we noted results favouring the exercise group(s) versus control. If we found analyses of the same outcome at more than one timepoint, we noted any comparison favouring the exercise intervention(s) over controls.

We labelled all outcomes reported in published manuscripts not linked to a 320 321 preregistered outcome score but related to (insufficiently) prespecified domain-only outcomes as 'domain-related' outcomes. For all domain-related outcomes, we checked whether the 322 descriptions of outcomes in the published manuscripts matched that of the registries (i.e., 323 324 primary and secondary domains in registry reported as primary and secondary outcomes in 325 publications, respectively) or whether switching had occurred. If no domain-related outcomes were reported in the available manuscripts, we noted this as 'domain-only outcomes not 326 327 reported'.

All outcomes reported in published manuscripts not linked to outcomes preregistered with or without an outcome score, were described as non-preregistered or 'novel' outcomes. We noted if authors had declared these 'novel' outcomes as non-preregistered (e.g., labelled as an exploratory or secondary analysis), and whether they described them as primary or secondary outcomes in the publications. We considered all undeclared novel outcomes as discrepancies.

Reporting consistency of preregistered outcomes with scores: clinical registries vs.

335 publications

For outcomes preregistered with scores, we assessed the consistency of reporting in published manuscripts (Figure 2). We noted if the outcome score, outcome method, assessment timepoints, and outcome analysis plan in the preregistration (and published protocols, if

available) matched the descriptions in the manuscripts. We considered reporting consistency
both with and without the statistical analysis item, due to the absence of this requirement in
registry guidance. In additional analyses, we assessed the completeness of statistical reporting
for each outcome, and details of this methods and findings can be found in Supplementary
Table 3.


344

345 **RESULTS**

346 Study selection

347 Our PubMed search using Secondary Source IDs resulted in 31 prospectively registered RCTs investigating the effects of at least partially supervised exercise interventions in cancer 348 populations across the selected clinical trial registries (Figure 3). The full list of eligible trials 349 350 with a reference list for published protocols and results manuscripts are provided in Supplementary Table 4, and a list of excluded trials with reasons is presented in Supplementary 351 Table 5. Most of the 31 trials were registered on Clinicaltrials.gov (n=22; 71%) and the 352 remaining trials were registered on ANZCTR (n=6; 19%), NTR (n=3; 10%; 1 of these 3 trials 353 was also registered on the ISRCTN registry). 354





355

Figure 3. PRISMA diagram of flow of studies 356

357

We found 46 trials that met all eligibility criteria except prospective registration 358 (Supplementary Table 6 and Supplementary Figure 1). These retrospective trials were 359 registered months after trial start dates in most case; there was a median delay of 202 days (IQR 360 =561; min-max = 19-1,770 days;). Most (n=40; 87%) were completed and had published 361 results, however, two were completed but had not published their results yet (last checked: 22nd 362 363 January 2021), two had been terminated [a reason was given for one: low recruitment (50)],

and one had been withdrawn. Only one of the retrospectively registered trials, the large multi-364 national INTERVAL GAP-4 trial, was currently recruiting (51).¹ 365

Our search also uncovered 11 trials that were eligible but had not published their results 366 at the time of writing (22nd January 2021) (Supplementary Table 7 and Supplementary Figure 367 2). Of these 11, we found four completed trials (i.e., actual trial completion dates were provided 368 in their registration). The median number of days from actual study completion to the present 369 day (22nd January 2021) was 366 days, but this time ranged between 205 and 1,075 days. One 370 other trial (52) was suspended (no reason provided). Six of the trials without published results 371 were ongoing trials, and only one had exceeded their anticipated completion date [721 days 372 over as of 22nd January 2020 (53)]. The remaining five studies had a median of 222 (min-max: 373 374 38-648) days from the time of writing to the anticipated study completion date (as recorded in the trial registrations). 375

Trial start dates were often difficult to establish from the registrations. We discovered 376 eight trials on ClinicalTrials.gov that modified their start dates during the study period. Because 377 we did not foresee this issue when writing our preregistration, we devised a *post hoc* solution 378 379 to establish eligibility. Where recruitment commenced after the start date modification, we accepted the new start date as a prospective registration. However, if a study changed their start 380 date after recruitment had already begun, according to their recruitment status, we rejected the 381 382 new start date and retained the original start date.

383

Two trials are noteworthy with respect to the above rule (54,55). First, Dieli-Conwright (54) initially recruited from May 2010 until the trial was suspended over a year later (14th 384

¹ According to the clinicaltrials.gov 'history of changes', the INTERVAL GAP-4 trial was registered on 31st March 2016 with a trial start date of December 2015 and the trial status was 'recruiting'. Although the trial start date was later changed on the 7th September 2017 (for reasons unknown) to January 2016, this new date still means the trial was retrospectively preregistered by at least 12 weeks.

October 2011). Then on 29th May 2012, the authors made substantial changes to the trial design 385 (new exercise prescription, intervention duration, patient eligibility, and primary and secondary 386 outcomes), before restarting the trial in May 2012. Due to the suspension of the trial in the 387 interim, the author team agreed by consensus to include it in OREO; we therefore, discarded 388 the original registration and accepted the new start date May 2012 was accepted as a 389 prospective registration. However, in another trial (55), recruitment was open for more than 390 two years (August 2012 to 11th January 2015) before the researchers moved the start date 391 forward from August 2012 to December 2014. Because the trial was not suspended and 392 393 extensive modifications were made to trial design (eligibility criteria, intervention characteristics, and outcomes) in the period between the two start dates, there was a consensus 394 that the new start date should be rejected. However, because the first trial registration was 395 396 submitted (September 2012) after the original start date (August 2012), the trial was considered retrospectively registered and excluded from OREO. No declarations regarding the 397 modifications to trial start dates, recruitment status, design, or outcomes were made in the 398 published manuscripts for this trial. 399

400

401 Study characteristics

The characteristics of the 31 eligible trials are presented in Supplementary Table 8. Just over 402 half of the trials (n=18) had published protocols, but only three trials published prospective 403 404 protocols [NCT03087461 (44,56);ACTRN12610000609055 (57,58);ACTRN12611001158954 (43,59)]. Excluding published protocols, we found a total of 78 405 published articles across all eligible trials, with a median of two results papers per trial (min-406 407 max: 1-7 papers; Supplementary Table 4).

408 Most trials had small sample sizes, with 17 (55%) trials comprising samples below 100 409 participants [median (min-max) participants per study: 65 (23-420)]. The most commonly 410 studied cancer type across trials was breast (n=13; 42%) followed by prostate (n=6; 19%).

411 Participants were aged on average 58 ± 8 years (mean \pm SD) across trials and had an average BMI in the 'overweight' category (mean \pm SD: $28 \pm 3 \text{ kg/m}^2$). Based on thirteen (42%) 412 trials with available ethnicity data, participants were mainly white (mean \pm SD: 72 \pm 26%). 413 414 From the 26 (84%) trials with cancer stage data, most patients had a diagnosis of either stage II or III cancer (57%). Most trials (n=17; 55%) comprised patients who had completed adjuvant 415 therapy (chemotherapy or radiotherapy), whereas 12 (39%) trials consisted of patients 416 417 receiving either chemotherapy or radiotherapy (n=9), androgen deprivation therapy (n=2), or 418 aromatase inhibitors (n=1), and two (6%) studies included patients awaiting surgery.

Most exercise interventions comprised both aerobic and resistance training (n=14; 420 45%), or aerobic exercise alone (n=9, 29%). Interventions were relatively short-term on 421 average (mean \pm SD: 18 \pm 13 weeks), and the two longest trials both lasted a year (60,61). We 422 found five (16%) partially supervised trials (less than half of prescribed exercise sessions were 423 supervised in-person), whereas all others were fully supervised (n=26; 84%).

424

425 **Completeness of preregistration**

All decisions made regarding the included trials can be accessed here: <u>https://bit.ly/3qFkcro;</u> and our raw data can be found here: <u>https://osf.io/4c8mb/</u>. In the 31 eligible trial registrations, we found a total of 405 prespecified outcomes: 71 were recorded as primary, and 334 were secondary outcomes (Figure 4). There were a median of 11 outcomes per registration (minmax: 1-59), and the median time between registration and trial start was 28 (0-785) days (Supplementary Figure 3).

The completeness of preregistration varied across trials (Table 2 and Supplementary 432 Figures 4-7). Only 25 of a total 405 outcomes (6.2%) were preregistered completely, that is, 433 the registration provided an outcome score with a method of measurement, assessments 434 timepoints, and a planned statistical analysis description. These 25 outcomes came from just 435 three studies (56,58,62). If we disregard a planned statistical analysis description as a necessary 436 437 element of preregistration, then still less than half of the outcomes would be completely 438 preregistered (n=175; 42.5%) and more than one-third of trials would have provided no preregistered outcomes (n=12; 38.7%; Table 2). 439

Assessment timepoints were provided for most preregistered outcomes (n=380, 93.8%), with 25 (80.7%) trials specifying timepoints for all outcomes listed, but four (12.5%) trials failed to report assessment timepoints for any listed outcome. However, only 61.5% of the 405 (n=249) preregistered outcomes specified a method of measurement. Only nine (29.0%) trials preregistered a measurement method for all their outcomes, whereas another 10 trials did not provide any measurement method in their registration.

Researchers preregistered an outcome score for 250 (61.7%) outcomes (Table 2). Six studies (19.3%) provided no outcome scores for any of their outcomes, and therefore, included no sufficiently preregistered outcomes (63–68). Only two (6.5%) trials provided an outcome score for all preregistered outcomes. Of the 155 (38.3%) outcomes where no score was preregistered, 68 (16.8%) provided a measurement method and 87 (21.5%) provided only the outcome domain with no method. A slightly higher percentage of preregistered primary outcomes were missing an outcome score than secondary outcomes (33.8% vs. 18.9%).

A planned statistical analysis was preregistered (either in registry entries or prospective published protocols) for 46 (11.4%) outcomes across three studies (30 from one trial: (58); 8 each from 2 studies: (56,62)]. These three studies provided an analysis plan for all their

456 outcomes. We found the statistical analysis plan for nine (2%) of outcomes in the registry 457 entries (from two trials) and obtained the remaining preregistered analysis plans from 458 prospective published protocols. One other trial reported two possible statistical approaches 459 (two-way, group x time repeated measures ANOVA or ANCOVA "as appropriate", with no 460 elaboration), and we, therefore, marked this study as not having stipulated a specific planned 461 statistical analysis (59).

462

	Ν	%
Total preregistered outcomes in trial registries and protocols		100
Preregistration across trials:		
Complete preregistration	25	6.2
Complete preregistration minus statistical analysis plan	175	43.2
Outcome domain-only provided (i.e. no outcome score)	155	38.3
Preregistration across outcomes:		
Measurement method provided	249	61.
Assessments timepoints provided	380	93.
Outcome score provided	250	61.
Planned analysis provided	46*	11.4
Outcome score registration across primary outcomes:		
Primary outcome score provided	39	54.
No outcome score or method provided	24	33.
No outcome score but measurement method provided	8	11.
Outcome score registration across secondary outcomes:		
Secondary outcome score provided	211	63.2
No outcome score or method provided	63	18.
No outcome score but measurement method provided	60	18.0

463 **Table 2.** The completeness of outcome preregistration

* For 38 of these outcomes, the information was taken from prospective published protocols


Reporting of outcomes prespecified with an outcome score in publications

Outcomes prespecified in a clinical registry with an outcome score and reported in publications
without outcome switching represented just 15.9% (148/929) of all published outcomes (i.e.
outcomes not omitted, prespecified primary outcomes reported as primary and prespecified
secondary outcomes reported as secondary in publications).

When we considered only outcomes preregistered with an outcome score, we found that most (59.2%; n=148/250) were published without switching or omission (Figure 4). More than a fifth (22.7%; n=92) of all preregistered outcomes with an outcome score, however, were not reported in publications, and 2.5% (n=10) were switched (9 were switched without declaration). Almost a third (n=10/32) of trials failed to report a single sufficiently preregistered outcome that was not switched or omitted from their published manuscripts.

We identified 39 sufficiently prespecified primary outcomes (i.e. with an outcome 476 score). Of these, the authors reported 28 (71.8%) correctly as primary outcomes in the 477 478 published papers (Figure 3), omitted five (12.8%) from published manuscripts [one study (69)] 479 provided their finding in the results section of the registry; the finding was not statistically significant], and reported six (15.4%) sufficiently prespecified primary outcomes as secondary 480 outcomes in the published papers (i.e. outcome switching). However, for one of the primary 481 outcome switches, the authors declared the switch and provided that the following reason: "the 482 need to reduce the study's sample owing to a reduction in funding" (60). Therefore, we found 483 484 five cases of undeclared outcome switches in primary outcomes with prespecified outcome scores. Taken together, 25.6% (n=10/39) of sufficiently prespecified primary outcomes were 485 486 switched for a secondary outcome without declaration or omitted from published manuscripts (secondary aim 1). 487

Researchers reported 120 (56.9%) of the 211 secondary outcomes that provided an outcome score correctly as secondary without switching or omission (secondary aim 2). We discovered a relatively large number of unreported sufficiently preregistered secondary outcomes (40.7%; n=87), and four (1.9%) cases of undeclared outcome switching (i.e. prespecified secondary outcomes were reported as primary outcomes; Figure 4).



493

494 **Figure 4.** Summary of the fates of outcomes reported in trial registries

495


496 **Reporting of domain-only outcomes**

We could link 81 (52.3%) outcomes preregistered as 'domain-only' (e.g., only 'fatigue' prespecified as an outcome in the registry and FACT-Fatigue total score reported in a linked publication) to published outcomes (Figure 4). Most (87.5%; n=28/32) primary outcomes that were preregistered without an outcome score (domain-only) had related outcomes in the published papers, whereas, a minority (43.1%; n=53/123) of secondary-domain-only outcomes related to published outcomes.

The remaining 47.7% (n=74) of the outcomes preregistered with only a domain were 503 not related to any published outcome (i.e. omitted outcomes). Most (56.9%; n=70/123) 504 domain-only outcomes dropped from publications were secondary outcomes; conversely, only 505 12.5% (n=4/32) of primary domain-only outcomes were omitted (Figure 4). Adding these 506 unreported outcomes to the 92 omitted preregistered outcomes with outcome scores (described 507 above), means that 41.0% (n=166) of all outcomes provided in registrations were omitted from 508 509 the available published manuscripts (Figure 4 and Table 3). This omission of preregistered outcomes is suggestive of selective outcome non-reporting. 510

Many of the outcomes preregistered without an outcome score were related to several 511 512 outcomes in publications, therefore, we found that over a third (35.3%; n=328/929) of outcomes in publications were linked to these domain-only outcomes (secondary aim 3A). Of 513 these outcomes, 22.9% (n=75) were reported as primary outcomes and 77.1% (n=253) as 514 515 secondary outcomes in the published manuscripts. However, we found evidence of outcome switching among these outcomes. More than a quarter of outcomes (26.7%; n=20) reported as 516 517 primary outcomes in eligible publications were related to domain-only registered secondary outcomes. Similarly, 22.1% (n=56) of outcomes reported as secondary in published articles 518 519 were related to primary outcomes preregistered as domain-only (Figure 5 and Table 3). Overall, 520 8.2% (n=76/929) of outcomes in published manuscripts were instances of outcome switching among domain-only preregistered outcomes (secondary aim 3B). An exploratory analysis 521 revealed that the odds of a domain-related outcome being switched was almost four times 522 523 greater than that of an outcome preregistered with an outcome score (Odds Ratio 3.97; 95% CI 2.12 to 8.16). 524





525

- Figure 5. Summary of outcomes published in eligible publications 526
- 527

Non-preregistered (novel) outcomes reported in eligible published manuscripts 528

Of the 929 published outcomes, only 17.1% (n=158) comprised outcomes prespecified with an 529 outcome score and 35.3% (n=328) were outcomes linked to domain-only outcomes in 530 preregistrations, therefore, most published outcomes (47.7%; n=443/929) were novel outcomes 531 (i.e. not related to any prespecified outcome) introduced after trial registration (Figure 5 and 532 Table 3). Authors reported 14.2% (n=63) of these novel outcomes as primary outcomes, and 533 534 85.8% (n=380) as secondary outcomes. Only 11.1% (n=49/443) of novel outcomes were declared as such (mostly by labeling the analysis as 'secondary', 'exploratory', or 'post hoc') 535 (secondary aim 4). Therefore, silently introduced (undeclared) outcomes represented 42.4% 536 (n=394; 61 primary and 335 secondary) of published outcomes (secondary aim 5; Table 3). A 537 median (min-max) of 10 (0-50) novel outcomes were silently introduced per trial. 538

Outcomes	Ν	%
Total outcomes in eligible publications		10
Outcomes labelled as primary outcomes in publications	170	18
Outcomes labelled as secondary outcomes in publications	759	81.
Discrepancies in outcomes		
Total discrepancies in outcomes labelled as primary	84	49.
Primary outcomes in publications that were preregistered as secondary outcomes with an outcome score (undeclared)	4	2.4
Primary outcomes in publications that were preregistered as secondary outcomes without outcome scores (undeclared)	20	11.
Undeclared novel outcomes published as a primary outcome	60	35.
Total discrepancies in outcomes labelled as secondary	395	52
Secondary outcomes in publications that were preregistered as primary outcomes with an outcome score (undeclared)	5	0.
Secondary outcomes in publications that were preregistered as primary outcomes without outcome scores (undeclared)	56	7.
Undeclared novel outcomes published as a secondary outcome	334	44
Total discrepancies across all outcomes (% published outcomes)	479	51
Total undeclared outcome switches	85	9.
Total undeclared novel outcomes	394	42
Preregistered outcomes omitted from publications		
Total preregistered outcomes omitted from publications (% of preregistered outcomes)	166	41
Omitted preregistered primary outcomes	9	2.
Omitted preregistered secondary outcomes	157	38
Number of trials with discrepancies and omitted preregistered outcomes:		
Trials with no discrepancies (i.e. no undeclared switching or novel outcomes)	4	12
Trials with no omitted preregistered outcomes		25
Trials with no discrepancies (i.e. no undeclared switching or novel outcomes) or omitted preregistered outcomes		3.

Table 3. Discrepancies in outcomes and omitted preregistered outcomes across eligible trials

543 Summary of discrepancies in outcomes published in eligible trial manuscripts

Overall, almost one in every 10 (9.1%) outcomes in published eligible trial manuscripts 544 were switched outcomes without declaration, and 42.4% were undeclared novel outcomes 545 (Table 3 and Supplementary Table 9). Half (49.4%) of the outcomes labelled as primary 546 outcomes in published manuscripts were switched or undeclared non-preregistered outcomes 547 (Table 3). Therefore, taken together, half (50.7%) of all published outcomes were either 548 549 switched or silently introduced post hoc. Twenty-seven (87.1%) of the 31 trials contained at least one discrepancy. Eight trials (25.8%) omitted preregistered outcomes. Only one (3.2%) 550 551 trial was free from switched, undeclared novel, or omitted outcomes [registration: (70); publication: (71)]. 552

553 Of the 152 correctly reported outcomes, 38 (25%) were described as statistically 554 significant. All four secondary outcomes promoted to primary outcomes in published 555 manuscripts were statistically significant. However, all five primary outcomes demoted to 556 secondary outcomes in published manuscripts also attained statistical significance. Of the 50 557 undeclared novel efficacy-related outcomes introduced as primary outcomes in publications, 558 22% (n=11) were statistically significant.

559

560 Proportion of published prespecified outcomes descriptions matching trial results 561 publications

We examined the consistency of reporting between preregistration and published outcomes by comparing the reporting of the outcome measurement method, assessment timepoints, outcome score, and statistical analysis of sufficiently prespecified outcomes (i.e. with an outcome score) in prospective registrations to the published manuscripts. Of the 158 (primary: 34; secondary: 124) prespecified outcomes in published manuscripts, the described preregistered measurement

method matched the published report for 116 (73.4%) cases, whereas the assessment timepoints
and outcome score were consistent for 96 (60.8%) and 146 (92.4%) cases, respectively.

There were 62 (39.2%) mismatches between assessment timepoints reported in registry 569 570 entries and published manuscripts, and most of these mismatches were due to omitted timepoints (74.2%; n=46/62). For the remaining inconsistencies, researchers introduced extra 571 timepoints for six (9.7%) outcomes (e.g., a non-preregistered follow-up assessment was 572 573 added), reduced the time between assessments for three (4.8%) outcomes, and extended the timepoints for one (1.6%) outcome (e.g., a preregistered post-intervention assessment for 12 574 weeks reduced to eight weeks or extended to 18 weeks in publication). For six (9.7%) outcomes 575 576 the preregistered assessment timepoints were unclear. When a pre-planned statistical analysis 577 was available, only eight (5.1%) of them matched that reported in the published protocol papers. 578

For the 25 completely preregistered outcomes (described above and in Table 3), the published description of only three outcomes matched the trial registry entry (secondary aim 6). These three outcomes came from one study (56) and were descriptive analyses of feasibility outcomes (recruitment, retention, and adherence). Therefore, we found no preregistered efficacy or effectiveness outcomes that were measured and assessed as planned when we consider prespecification of measurement method, outcome score, assessment timepoints, and planned statistical analysis as essential components of preregistration.

If we exclude statistical analysis plans, descriptions of measurement method, assessment timepoints, and outcome scores in the clinical trial registrations matched that reported in published manuscripts for only 60 (38% of 158 sufficiently preregistered outcomes; and 6.5% of published outcomes) outcomes (only 12 of these were primary outcomes).

All descriptions of preregistered outcomes with a score matched that in the published report in just four trials (72–75); however, these trials also comprised insufficiently preregistered (domain-only) outcomes, omitted outcomes, and undeclared novel outcomes. Therefore, no trial was free of inconsistencies (i.e. insufficiently described prespecified outcomes, unmatched outcome descriptions, switched outcomes, and undeclared novel outcomes).






Figure 6. Percentage of sufficiently registered outcomes where the preregistered descriptions of measurement method, assessment timepoints, outcome score, and statistical analysis match the description in the published manuscripts. 'Method, time, score' = descriptions of preregistered measurement method, assessment timepoints, and outcome score matches published manuscript. 'Complete' = all preregistered elements of the outcome description match the published manuscript. 'Both' = both primary and secondary outcomes.

603

604 **DISCUSSION**

605 Our current analysis aimed to evaluate selective outcome reporting in exercise oncology RCTs

606 by comparing prospective trial registrations with their associated published articles. We found

trial registrations lacking essential details, and widespread evidence of outcome switching and

reporting bias. None of the 78 published articles from the 31 trials were free from incomplete, inconsistent, or selectively reported outcomes. Fewer than 20% of outcomes reported in published manuscripts were sufficiently preregistered and presented without switching, and 42% of published outcomes were silently introduced (undeclared) novel outcomes. Furthermore, when we compared descriptions of sufficiently prespecified outcomes in registry entries to published manuscripts, we found inconsistencies for all but three outcomes from one study. These findings raise questions about the integrity of the exercise oncology literature.

615 *Prospective and retrospective trial registrations*

Despite the ICMJE (18), WHO (19), and the Declaration of Helsinki (17) mandating that every 616 617 clinical trial is registered in a publicly accessible database before recruitment of the first participant, we discovered 46 otherwise eligible exercise oncology RCTs that were 618 retrospectively registered. Although these retrospectively registered trials in our search results 619 620 started years after the launch of such requirements (100% were registered in or after 2005; 80% were registered in or after 2008), most were registered months or even years after the first 621 patient was enrolled. Therefore, more than 50% of trials that met all other eligibility criteria 622 were not compliant with international standards [e.g. WHO and WMA (19)] for clinical 623 research. 624

625 *Outcome switching, omission, and silent introduction*

The most critical type of discrepancy involves the switching of a preregistered primary outcome for a non-primary outcome in the published article. Researchers select the primary outcome in advance as the most clinically relevant measure that addresses the trial's main aim. As a rule, sample size justifications are based on the sample size required to detect an effect on the primary outcome (76). Changing the primary outcome threatens the validity of a study and can lead to an overestimation of intervention effects (77). Therefore, it is worrying that half (n=84) of the 170 outcomes labelled as 'primary' in published manuscripts were either

undeclared promotions of outcomes preregistered as secondary outcomes or silently introduced
novel outcomes. Only 28 outcomes labelled as 'primary' in published manuscripts were
prespecified with an outcome score in a registry entry or protocol paper, and another 55 could
be linked to a domain-only preregistered outcome.

We observed similar practices in secondary outcomes: 395 (52.0%) of the 759 outcomes labelled as 'secondary' in published manuscripts were undeclared switches or silently introduced novel outcomes. Just 15.8% of outcomes labelled as 'secondary' in publications were preregistered secondary outcomes with scores, whereas another 26.0% were related to preregistered secondary domain-only outcomes. Switching and omission were widespread and were absent from only four of the eligible trials.

Of note, 41% of all preregistered outcomes were omitted from published manuscripts.
Researchers, however, omitted secondary outcomes more often than primary outcomes (38.8%
vs. 2.2%). Only eight trials had no omitted outcomes, and just one was free of any discrepancies
(i.e. no undeclared switching or novel outcomes) or omitted preregistered outcomes. Similarly,
most trials (n=26) silently introduced novel outcomes in the published results manuscripts.
These novel outcomes accounted for 42% of all outcomes reported in the manuscripts, with a
median of 14 outcomes silently introduced per trial.

Our findings are consistent with other studies that have explored discrepancies between registry entries and published manuscripts. A 2008 systematic review of studies exploring outcome reporting bias in RCTs of healthcare interventions discovered that one or more primary outcomes were changed, introduced, or omitted in 40–62% of studies (9). A later systematic review in 2015 detected a similar proportion of trials [median 31%; IQR 17–45%] with a discrepancy between the registered and published primary outcome (24). Goldacre and colleagues (26) observed that outcome misreporting is also common in top medical journals

that endorse the CONSORT statement, with outcome discrepancies requiring a correction letteridentified in 87% of included trials.

Deviations from preregistered protocols are a normal part of the scientific process and 659 are not unexpected when the process involves a complex behavioural intervention, such as 660 exercise, and a heterogeneous population like patients with cancer. Considering the volume of 661 discrepancies between preregistered and published outcomes we observed, surprisingly, only 662 663 one study transparently declared an outcome switch (78). When researchers do not provide such acknowledgements, one cannot rule out the possibility that the researchers' preference 664 towards a certain (often favourable) finding motivated the decision to omit outcomes and not 665 666 declare discrepancies between the preregistration and the published article. One major incentive for such outcome switching and selective outcome reporting is publication bias—the 667 historical preferential publishing of positive findings and studies that find support for their 668 hypothesis (79). Regardless of the motivation, however, failure to declare such deviations 669 contravenes the Declaration of Helsinki and leads to published articles that are dishonest, 670 misleading, and potentially harmful to patients (80). 671

672 Vague preregistration and inconsistent reporting of outcomes

Authors of clinical trial registrations must describe their primary and secondary 673 outcomes in sufficient detail (akin to reporting enough detail in a methods section to allow 674 replication by independent researchers). For example, describing an outcome simply as 675 'fatigue' (domain only) is vague and would be unacceptable in a scientific article. In exercise 676 science, fatigue can refer to both a subjective experience and an objective change in task 677 performance. In the present context, fatigue refers most often to a construct that is measured as 678 a patient-reported outcome, but many validated questionnaires exist for this purpose, and some 679 include both sub-scales and a total score. Therefore, when vague terms such as 'fatigue' are 680 681 used, readers have no way of ascertaining which questionnaire and score the researchers

originally selected to assess this outcome. Unfortunately, we found many such examples of poor reporting quality across the 31 trial registrations, which hampered our task of evaluating reporting bias. We found that 35.3% of outcomes were provided without outcome scores (domain-only), and six studies (19.4%) provided no scores for any of their outcomes, and therefore, included no sufficiently preregistered outcomes.

We evaluated outcome preregistration on five levels: the domain, measurement method, outcome score, assessment timepoint, and planned statistical analysis [modified from Zarin et al. (45)]. We found just 26 (6% of outcomes in trial registrations) outcomes that included all five levels (i.e. completely preregistered outcomes), and authors accurately reported only three of these outcomes [all from one trial (56)] in the published article (i.e. descriptions in publications matched the registration). Unfortunately, none of the outcomes were healthrelated outcomes— all three outcomes were feasibility-related.

When we excluded the requirement of a planned statistical analysis (which is usually a 694 695 requirement for institutional review board review and approval, but not an element for clinical 696 trial registries), we found that less than half of the preregistered outcomes were reported with all other components, and only 38% were reported consistently in the published article (i.e. a 697 match between registration and publication outcome descriptions). Only 12 of these outcomes 698 were primary outcomes, and of these: one was switched to a secondary outcome in the 699 published report [in trial (81)], three were feasibility outcomes [mentioned above from the 700 701 Bridging the Gap trial (56)], and only eight were efficacy outcomes reported correctly, albeit without a prespecified analysis plan. Interestingly, the statistical analysis of only three of the 702 703 eight primary outcomes produced a p-value below 0.05 (the most common threshold for 'statistical significance') in favour of the intervention group. We identified no trials free from 704 outcome switching, omission, or misreporting. 705

706 Although researchers could provide an ambiguous description of outcomes unintentionally, the result is that it masks the researcher's degrees of freedom at the point of 707 analysis and dissemination. Vague outcome descriptions bestow researchers with the flexibility 708 709 to choose their preferred measurement of the construct (e.g. if two fatigue questionnaires have been included), metric or scoring method (e.g. prioritizing a specific subscale) and assessment 710 timepoint. Moreover, when researchers do not provide a planned statistical analysis in advance, 711 712 they have greater flexibility to analyze the data in many ways using different statistical approaches and models. Researchers can then select, often based on the direction, size or 713 714 statistical significance (e.g., p < 0.05) of an effect, the approach or model that produced their favoured result and discard less favourable ones. Although this undisclosed flexibility in 715 outcome and analysis selection may increase the likelihood of publishing, it inflates the Type 716 717 1 error rate to an unknown extent and increases the likelihood that the preferred 'positive' findings presented in the published article occurred by chance alone. In other words, published 718 articles may are more likely to include false positives and exaggerate the benefits of an exercise 719 720 intervention.

Exercise is considered medicine in oncology (82), but for key stakeholders to 721 appropriately recognize exercise as adjunct care, exercise RCTs must be conducted and 722 reported as intended-to minimize bias. RCT design seeks to provide high-quality evidence 723 about the causal relationship between an intervention and an outcome by lowering harmful 724 biases to a greater extent than observational studies (83). Important RCT elements such as 725 726 random sequence generation and allocation concealment (selection bias) and the blinding (masking) of trial personnel and participants (performance and detection bias), when applied 727 appropriately, can increase the likelihood the study's findings are accurate estimates of the true 728 effect (84). However, flaws in the design, conduct, analysis, and reporting of RCTs can 729 undermine their ability to yield reliable causal inferences and produce underestimates or 730

overestimates of the true intervention effect (i.e. bias) (85). Efforts to minimize biases in trial design and conduct are futile if the subjective influence of the researcher is embraced at the point of analysis and dissemination (reporting bias). Reporting bias in exercise oncology trials undermines not only individual RCTs, but also any systematic reviews with meta-analyses for which the individual RCTs are eligible. Furthermore, the credibility and certainty of position stands and clinical recommendations (4,7,86,87) may be weakened if they are informed by evidence afflicted with reporting bias.

Although prospective trial registration did not appear to prevent reporting bias, it has 738 allowed us to evaluate the existence of this bias in the exercise oncology literature. We 739 740 encourage those wishing to evaluate the robustness of a finding reported in a registered exercise 741 oncology trial publication by 1) checking that the outcome of interest is present, described in sufficient detail, and prospectively registered by inspecting the history of revisions record in 742 743 the clinical trial registration, and 2) scrutinising the published manuscript for any declaration of a discrepancy (e.g. a reason why the outcome is missing or switched) compared with the 744 745 trial registration. Prospective registration of a clinical trial registry is not yet a sufficient deterrent against reporting bias, therefore, alongside raising awareness about this issue, other 746 747 solutions should be considered.

748 The Solutions

Clinical trials (see ICMJE definition) involving exercise for people with cancer must be prospectively registered before recruitment of the first participant. Prospective trial registration is not optional for researchers, they have a scientific and ethical responsibility to participants to comply, and we call for funders, editors, article reviewers, researchers and other stakeholders in exercise oncology to consider it mandatory. Specifying outcomes in sufficient detail (all 5 levels of outcome specification in Figure 1) is paramount; we observed a higher prevalence of outcome switching in outcomes described without an outcome score in trial registrations.

Transparent reporting and justifying deviations from the registered protocol (in Supplementary
Material or an open archive) is a normal part of the scientific process and should be adopted as
the standard by exercise oncology researchers (as recommended by CONSORT guidelines;
<u>http://www.consort-statement.org/</u>). Without such detail, readers can not easily establish which
outcome analyses are confirmatory or exploratory in published articles.

Trial registrations serve important functions for promoting the fulfillment of ethical 761 762 obligations to participants and the research community, such as providing information to potential participants and referring clinicians and providing a public record of study outcomes 763 and results. However, conceptually preregistration allows independent researchers to 764 765 transparently evaluate the capacity of a trial or test to falsify a prediction [the severity of a test; 766 see Lakens (88)]. This independent evaluation is not possible if the clinical trial registration is lacking key aspects in comparison to the more comprehensive preregistration standards that 767 768 have arisen from the replication crisis in psychology (89-91). The absence of statistical analysis plans from most of the trial registrations included in our sample precludes an 769 assessment of how severely the predictions they made were tested. Therefore, currently, most 770 of the exercise oncology trials may only provide what Professor Deborah Mayo, one of the 771 772 chief proponents of severity testing, describes as 'bad evidence, no test' (92). One potential 773 solution to improve preregistration quality is to preregister using SPIRIT reporting guidelines [www.spirit-statement.org; (93)] and platforms that guide and support detailed preregistration 774 such as the Open Science Framework (www.osf.io) and AsPredicted (www.aspredicted.org). 775

Considering the (often public) investment of resources and participant time and effort,
the field of exercise oncology should also consider adopting the registered report format (94).
Registered reports are a publishing model that seeks to address selective reporting bias and
publication bias (79). The key innovation with registered reports is that peer-review is split into
two stages, the first stage takes place *before* participant enrollment, whereas the second occurs

after the authors complete the study and submit the final report (for a primer related to exercise 781 science, see Caldwell et al. (95)). The importance of the research question and the validity and 782 rigour of the proposed methods and analysis plan can be assessed (and strengthened) in advance 783 during the first stage. If the reviewers agree that the question is important and the methodology 784 to test it is appropriate, then an "in-principle acceptance" can be granted. This means that the 785 results will be published regardless of the outcome (null or otherwise), assuming the 786 787 researchers followed their protocol, declared any deviations, and interpreted the results according to the evidence. Registered reports, like preregistration, can also help limit 788 789 undisclosed analytic flexibility (the garden of forking paths) because they include an analysis plan (91,94). BMC Medicine became the first clinical research journal to offer the registered 790 report format in 2017, and the first registered report in exercise oncology will signify a 791 792 welcome step for the field toward increased transparency.

793 Limitations and Future Directions

We excluded trial registrations that included unsupervised exercise interventions and exercise combined with other intervention components. Therefore, our analysis is not necessarily representative of the exercise oncology literature more broadly, though we have little reason to suggest that the inclusion of these studies would alter our main findings. We could not include 11 trials because they lacked published articles at the time of our search dates. Given that these are more recent trials, we will note with interest if outcomes published in future articles are more closely aligned with their trial registrations.

During our analysis, we made several additional decisions regarding the preregistration of outcome scores were made that were not prespecified in our preregistered protocol; these decisions are outlined with a rationale in Supplementary Table 2. Aside from additional decisions; our primary protocol deviations were as follows: we did not consider each time point as a separate outcome (instead we noted whether assessments for each outcome were reported

806 at each timepoint); we excluded cross-sectional and mediation analysis publications from our main analyses (although this was perhaps explicit from our aim to study 'intervention effects'); 807 we used multiple authors for data entry (instead of a single author); and we added an 808 exploratory analysis investigating the odds of outcome switching for a domain-related outcome 809 versus an outcome preregistered with a score (Supplementary Table 10). Furthermore, during 810 the data entry process, we introduced a process for the categorisation of the level of outcome 811 registration (as either "outcome domain only", "partial" or "complete") to allow us to identify 812 the sources of selective outcome reporting and switching. We planned several secondary 813 814 analyses that arose from the data that were not preregistered and will be reported in subsequent articles. 815

816

817 CONCLUSIONS

Half of otherwise eligible exercise RCTs in people diagnosed with cancer were retrospectively 818 registered and, therefore, did not meet current international standards for clinical trials. Across 819 31 prospective trial registrations, we found evidence suggestive of widespread selective 820 outcome reporting and non-reporting bias. The existence of such outcome reporting bias has 821 implications for the integrity and credibility of randomized trials in exercise oncology. The 822 omission of potentially non-statistically significant, 'negative', or small effects in favour of 823 824 more 'positive' or novel findings could be distorting the exercise oncology literature, leading 825 to potentially inaccurate claims about the potential benefits or harms of exercise for people with cancer. Sufficient trial preregistration along with transparent reporting of outcomes and 826 deviations from trial protocols in future exercise oncology trials is warranted to better 827 828 understand the role of exercise in cancer care.

829

830

831 **AUTHOR CONTRIBUTIONS:**

Task	Responsibility of
Conceptualization	BS (Equal), CMF (Equal), JFC (Equal), KAB (Equal), RT
	(Support), DN (Equal), IML (Equal)
Data Curation	BS (Equal), CMF (Equal), KAB (Support), RT (Support), DN
	(Support), IML (Equal)
Formal Analysis	BS (Support), IML (Lead)
Funding Acquisition	Not applicable
Investigation	BS (Equal), CMF (Equal), KAB (Support), RT (Support), DN
	(Support), IML (Equal)
Methodology	BS (Equal), CMF (Equal), JFC (Equal), KAB (Equal), RT
	(Equal), DN (Equal), IML (Equal)
Project Administration	BS (Lead), IML (Support)
Resources	BS (Support), IML (Lead)
Software	BS (Support), IML (Lead), CMF (Support)
Supervision	IML (Lead)
Validation	BS (Equal), CMF (Equal), KAB (Equal), RT (Equal), IML
	(Equal)
Visualization	BS (Support), IML (Lead)
Writing (Original Draft)	BS (Lead), IML (Support), RT (Support)
Writing (Review &	BS (Equal), CMF (Equal), JFC (Equal), KAB (Equal), RT
Editing)	(Equal), DN (Equal), IML (Equal)

832 Contributor Roles Taxonomy (CRediT: <u>http://credit.niso.org</u>):

833

834 **REFERENCES**

835 836 837	1.	Babbage C. Reflections on the Decline of Science in England: And on Some of Its Causes [Internet]. B. Fellowes; 1830. 309 p. Available from: http://archive.org/details/reflectionsonde00mollgoog
838 839	2.	Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017). PM R. 2017 Sep;9(9S2):S347–84.
840 841 842	3.	Fuller JT, Hartland MC, Maloney LT, Davison K. Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br J Sports Med. 2018 Oct;52(20):1311.
843 844 845	4.	Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375.
846 847	5.	Segal R, Zwaal C, Green E, Tomasone JR, Loblaw A, Petrella T. Exercise for people with cancer: a clinical practice guideline. Curr Oncol. 2017 Feb;24(1):40–6.
848 849 850 851	6.	Schmitz KH, Stout NL, Maitin-Shepard M, Campbell A, Schwartz AL, Grimmett C, et al. Moving through cancer: Setting the agenda to make exercise standard in oncology practice. Cancer [Internet]. [cited 2020 Oct 28];n/a(n/a). Available from: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.33245

- Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, et al. Clinical Oncology Society of
 Australia position statement on exercise in cancer care. Med J Aust. 2018 Aug 1;209(4):184–7.
- 854 8. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—
 855 GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr
 856 1;64(4):383–94.
- 9. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, et al. Systematic Review of the
 Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PLOS ONE. 2008 Aug
 28;3(8):e3081.
- Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical Evidence for Selective
 Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles.
 JAMA. 2004 May 26;291(20):2457–65.
- 11. Chan A-W, Krleža-Jerić K, Schmid I, Altman DG. Outcome reporting bias in randomized trials
 funded by the Canadian Institutes of Health Research. CMAJ. 2004 Sep 28;171(7):735–40.
- Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published
 primary outcomes in randomized controlled trials. JAMA. 2009 Sep 2;302(9):977–84.
- Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome
 reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ [Internet].
 2010 Feb 15 [cited 2020 Oct 27];340. Available from:
 https://www.bmj.com/content/340/bmj.c365
- Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat
 Methods Med Res. 2005 Oct 1;14(5):515–24.
- Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, editors.
 Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons;
 2019. p. 297–334.
- 876 16. WHO data set [Internet]. [cited 2021 Jan 7]. Available from: https://www.who.int/clinical-trials 877 registry-platform/network/who-data-set
- Krleža-Jerić K, Lemmens T. 7th Revision of the Declaration of Helsinki: Good News for the
 Transparency of Clinical Trials. Croat Med J. 2009 Apr;50(2):105–10.
- 18. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a
 statement from the International Committee of Medical Journal Editors. JAMA. 2004 Sep
 15;292(11):1363–4.
- 19. International standards for clinical trial registries 2nd edition. Geneva: World Health
 Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
- 20. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw JM, et al. Compliance of
 clinical trial registries with the World Health Organization minimum data set: a survey. Trials.
 2009 Jul 22;10(1):56.
- 21. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB. Issues in the Registration of Clinical
 Trials. JAMA. 2007 May 16;297(19):2112–20.

- 890 22. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. Proc Natl Acad
 891 Sci U S A. 2018 13;115(11):2600–6.
- Wagenmakers E-J, Wetzels R, Borsboom D, van der Maas HLJ, Kievit RA. An Agenda for Purely
 Confirmatory Research. Perspect Psychol Sci J Assoc Psychol Sci. 2012 Nov;7(6):632–8.
- 24. Jones CW, Keil LG, Holland WC, Caughey MC, Platts-Mills TF. Comparison of registered and
 published outcomes in randomized controlled trials: a systematic review. BMC Med [Internet].
 2015 Nov 18 [cited 2021 Jan 7];13. Available from:
- 897 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650202/
- 898 25. Bradley HA, Rucklidge JJ, Mulder RT. A systematic review of trial registration and selective
 899 outcome reporting in psychotherapy randomized controlled trials. Acta Psychiatr Scand.
 900 2017;135(1):65–77.
- 901 26. Goldacre B, Drysdale H, Dale A, Milosevic I, Slade E, Hartley P, et al. COMPare: a prospective
 902 cohort study correcting and monitoring 58 misreported trials in real time. Trials. 2019 Feb
 903 14;20(1):118.

27. Ioannidis JPA, Munafò MR, Fusar-Poli P, Nosek BA, David SP. Publication and other reporting
 biases in cognitive sciences: detection, prevalence, and prevention. Trends Cogn Sci. 2014 May
 1;18(5):235–41.

28. Dwan K, Kirkham JJ, Williamson PR, Gamble C. Selective reporting of outcomes in randomised
 controlled trials in systematic reviews of cystic fibrosis. BMJ Open. 2013 May 1;3(6):e002709.

29. Jones PM, Chow JTY, Arango MF, Fridfinnson JA, Gai N, Lam K, et al. Comparison of Registered
and Reported Outcomes in Randomized Clinical Trials Published in Anesthesiology Journals.
Anesth Analg. 2017 Oct;125(4):1292–300.

30. Jones CW, Misemer BS, Platts-Mills TF, Ahn R, Woodbridge A, Abraham A, et al. Primary
outcome switching among drug trials with and without principal investigator financial ties to
industry: a cross-sectional study. BMJ Open. 2018 Feb 1;8(2):e019831.

- 31. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of
 antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008 Jan
 17;358(3):252–60.
- 32. Aggarwal R, Oremus M. Selective outcome reporting is present in randomized controlled trials in
 lung cancer immunotherapies. J Clin Epidemiol. 2019 Feb 1;106:145–6.
- 33. Falk Delgado A, Falk Delgado A. Outcome switching in randomized controlled oncology trials
 reporting on surrogate endpoints: a cross-sectional analysis. Sci Rep [Internet]. 2017 Aug 23
- 922 [cited 2019 Feb 25];7. Available from:
- 923 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569019/
- 34. Tan TH, Chen D, Soon YY, Tey JCS. Prevalence and predictors of bias in the reporting of primary
 efficacy and toxicity endpoints in randomized clinical trials of radiation oncology. J Med Imaging
 Radiat Oncol. 2016 Dec;60(6):764–71.
- 927 35. van der Steen JT, ter Riet G, van den Bogert CA, Bouter LM. Causes of reporting bias: a
 928 theoretical framework. F1000Research. 2019 Jul 17;8:280.

- 36. McGauran N, Wieseler B, Kreis J, Schüler Y-B, Kölsch H, Kaiser T. Reporting bias in medical
 research a narrative review. Trials. 2010 Apr 13;11(1):37.
- 37. Gall T, Ioannidis JPA, Maniadis Z. The credibility crisis in research: Can economics tools help?
 PLOS Biol. 2017 Apr 26;15(4):e2001846.
- 38. Winter EM, Fowler N. Exercise defined and quantified according to the Systeme International
 d'Unites. J Sports Sci. 2009 Mar;27(5):447–60.
- 39. Courneya KS. Efficacy, effectiveness, and behavior change trials in exercise research. Int J Behav
 Nutr Phys Act. 2010 Nov 12;7(1):81.
- 937 40. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical Trial Registration: A
 938 Statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004 Sep
 939 16;351(12):1250–1.
- 41. Learn About Clinical Studies ClinicalTrials.gov [Internet]. [cited 2021 Jan 14]. Available from:
 https://clinicaltrials.gov/ct2/about-studies/learn
- 42. Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, et al. Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE). Cancer. 2015
 43. Aug;121(15):2646–54.
- 946 43. Galvão DA, Taaffe DR, Cormie P, Spry N, Chambers SK, Peddle-McIntyre C, et al. Efficacy and
 947 safety of a modular multi-modal exercise program in prostate cancer patients with bone
 948 metastases: a randomized controlled trial. BMC Cancer. 2011 Dec;11:517.
- 949 44. Smith-Turchyn J, Richardson J, Tozer R, McNeely M, Thabane L. Bridging the Gap: Incorporating
 950 Exercise Evidence into Clinical Practice in Breast Cancer Care in Ontario-A Pilot Randomized
 951 Control Trial Protocol. Cancer Stud Ther. 2017 Jul 1;2.
- 45. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov Results Database Update
 and Key Issues. N Engl J Med. 2011 Mar 3;364(9):852–60.
- 954 46. Submit Studies ClinicalTrials.gov [Internet]. [cited 2021 Jan 14]. Available from:
 955 https://clinicaltrials.gov/ct2/manage-recs
- 956 47. ClinicalTrials.gov Protocol Registration Data Element Definitions for Interventional and
 957 Observational Studies [Internet]. [cited 2021 Jan 14]. Available from:
 958 https://prsinfo.clinicaltrials.gov/definitions.html
- 48. Lakens D. The Value of Preregistration for Psychological Science: A Conceptual Analysis
 [Internet]. PsyArXiv; 2019 Nov [cited 2020 Nov 27]. Available from: https://psyarxiv.com/jbh4w/
- 961 49. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010
 962 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials.
 963 BMJ [Internet]. 2010 Mar 24 [cited 2020 Nov 27];340. Available from:
 964 https://www.bmj.com/content/340/bmj.c869
- 965 50. Pedersen JH. Perioperative Rehabilitation in Operation for Lung Cancer [Internet].
 966 clinicaltrials.gov; 2015 May [cited 2021 Jan 21]. Report No.: NCT01893580. Available from: 967 https://clinicaltrials.gov/ct2/show/NCT01893580

- 968 51. Newton R, Saad F. INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer
 969 (INTERVAL GAP4): A Multicentre, Randomised, Controlled, Phase III Study [Internet].
 970 clinicaltrials.gov; 2020 Aug [cited 2021 Jan 21]. Report No.: NCT02730338. Available from:
 971 https://clinicaltrials.gov/ct2/show/NCT02730338
- 52. Cuesta-Vargas AI. Effectiveness of an Individualized Program of Muscular Strength and
 Endurance Program With Aerobic Training for Improving Germ Cell Cancer Related Fatigue in
 Men Undergoing Chemotherapy [Internet]. clinicaltrials.gov; 2019 Sep [cited 2021 Jan 21].
 Report No.: NCT02433197. Available from: https://clinicaltrials.gov/ct2/show/NCT02433197
- 53. Liu L. An integrative Tai Chi program for breast cancer patients undergoing cancer therapy: A
 randomized controlled feasibility study [Internet]. The Australian New Zealand Clinical Trials
 Registry; 2017 Jun [cited 2021 Jan 22]. Report No.: ACTRN12617000975392. Available from:
 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373238
- 980 54. Dieli-Conwright C. Combined Exercise Program for Early Breast Cancer Survivors [Internet].
 981 clinicaltrials.gov; 2010 Jun [cited 2021 Jan 24]. Report No.: NCT01140282. Available from:
 982 https://clinicaltrials.gov/ct2/show/NCT01140282
- 983 55. de Almeida EPM. Effect of an Early Mobilization Program After Surgery on Functional Recovery
 984 and Clinical Complications in Patients Undergoing Major Cancer Surgey : a Randomized
 985 Controlled Trial [Internet]. clinicaltrials.gov; 2012 Sep [cited 2021 Jan 24]. Report No.:
 986 NCT01693172. Available from: https://clinicaltrials.gov/ct2/show/NCT01693172
- 56. Smith-Turchyn J. Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in
 Breast Cancer Care in Ontario [Internet]. clinicaltrials.gov; 2017 Mar [cited 2021 Jan 21]. Report
 No.: NCT03087461. Available from: https://clinicaltrials.gov/ct2/show/NCT03087461
- 57. Livingston PM, Salmon J, Courneya KS, Gaskin CJ, Craike M, Botti M, et al. Efficacy of a referral
 and physical activity program for survivors of prostate cancer [ENGAGE]: Rationale and design
 for a cluster randomised controlled trial. BMC Cancer. 2011;11(1):237.
- 58. Livingston T. The Efficacy of a Referral and Physical Activity Program, Compared to Usual Care,
 for Survivors of Prostate Cancer to Increase Participation in Physical Activity [Internet]. The
 Australian New Zealand Clinical Trials Registry; 2010 Jul [cited 2021 Jan 22]. Report No.:
 ACTRN12610000609055. Available from:
- 997https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335758&showOriginal=true&998isReview=true
- 59. Galvão D. The effect of multi-modal exercise versus usual care on physical function in prostate
 cancer patients with bone metastases. [Internet]. The Australian New Zealand Clinical Trials
 Registry; 2011 Apr [cited 2021 Jan 22]. Report No.: ACTRN12611001158954. Available from:
 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=347673&showOriginal=true&
 isReview=true
- 1004 60. Schmitz K. The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and
 1005 Cost Effectiveness of Alternative Management Strategies [Internet]. clinicaltrials.gov; 2012 Jan
 1006 [cited 2021 Jan 21]. Report No.: NCT01515124. Available from:
 1007 https://clinicaltrials.gov/ct2/show/NCT01515124
- 1008 61. Schmitz K. The PAL Trial (Physical Activity and Lymphedema) [Internet]. clinicaltrials.gov; 2005
 1009 Sep [cited 2021 Jan 21]. Report No.: NCT00194363. Available from:
 1010 https://clinicaltrials.gov/ct2/show/NCT00194363

1011 62. Dieli-Conwright C. High-Intensity Interval Training (HIT) for Breast Cancer Patients During Trastuzumab Use [Internet]. clinicaltrials.gov; 2015 May [cited 2021 Jan 21]. Report No.: 1012 1013 NCT02454777. Available from: https://clinicaltrials.gov/ct2/show/NCT02454777 1014 63. Kiecolt-Glaser J. Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress [Internet]. clinicaltrials.gov; 2014 Apr [cited 2021 Jan 21]. Report No.: NCT00486525. Available 1015 1016 from: https://clinicaltrials.gov/ct2/show/NCT00486525 1017 64. Courneya K. Randomized Controlled Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors. The CARE Trial. [Internet]. clinicaltrials.gov; 2005 Nov [cited 2021 Jan 21]. 1018 1019 Report No.: NCT00249015. Available from: https://clinicaltrials.gov/ct2/show/NCT00249015 1020 65. Scott J. Exercise Intensity Trial (EXCITE): A Randomized Trial Comparing the Effects of Linear 1021 Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer [Internet]. 1022 clinicaltrials.gov; 2010 Aug [cited 2021 Jan 21]. Report No.: NCT01186367. Available from: 1023 https://clinicaltrials.gov/ct2/show/NCT01186367 1024 66. Rogers L. Physical Activity Benefits After Breast Cancer: Exploring Cytokine Mechanisms 1025 [Internet]. clinicaltrials.gov; 2010 Jun [cited 2021 Jan 21]. Report No.: NCT01147367. Available 1026 from: https://clinicaltrials.gov/ct2/show/NCT01147367 1027 67. Winters-Stone K. Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses 1028 [Internet]. clinicaltrials.gov; 2009 Aug [cited 2021 Jan 21]. Report No.: NCT00954044. Available 1029 from: https://clinicaltrials.gov/ct2/show/NCT00954044 1030 68. van Waart H. Effectiveness of physical exercise during chemotherapy to improve physical fitness 1031 and reduce fatigue: A randomized trial. [Internet]. Netherlands Trial Register; 2010 Jan [cited 1032 2021 Jan 22]. Available from: https://www.trialregister.nl/trial/2042 1033 69. Mustian K. A Study of the Effects of Exercise on Cancer-Related Fatigue [Internet]. 1034 clinicaltrials.gov; 2009 Jun [cited 2021 Jan 21]. Report No.: NCT00924651. Available from: 1035 https://clinicaltrials.gov/ct2/show/NCT00924651 1036 70. Rydwik E. Preoperative Home-based Exercise in Older People Before Colorectal Surgery - a 1037 Feasibility Study [Internet]. clinicaltrials.gov; 2016 Sep [cited 2021 Jan 25]. Report No.: 1038 NCT02895464. Available from: https://clinicaltrials.gov/ct2/show/NCT02895464 1039 71. Karlsson E, Farahnak P, Franzén E, Nygren-Bonnier M, Dronkers J, Meeteren N van, et al. 1040 Feasibility of preoperative supervised home-based exercise in older adults undergoing colorectal 1041 cancer surgery – A randomized controlled design. PLOS ONE. 2019 Jul 2;14(7):e0219158. 1042 72. O'Donnell D, Hussey J, Walsh J. Individually Prescribed Exercise Versus Usual Care in a 1043 Heterogeneous Cancer Survivor Population: A Pragmatic Randomized Controlled Trial [Internet]. 1044 clinicaltrials.gov; 2009 Dec [cited 2021 Jan 24]. Report No.: NCT01030887. Available from: 1045 https://clinicaltrials.gov/ct2/show/NCT01030887 73. Bjerre E. Effectiveness of Community-based Football Compared With Usual Care on Quality of 1046 1047 Life in Men With Prostate Cancer: the FC Prostate Community Randomized Controlled Trial 1048 [Internet]. clinicaltrials.gov; 2015 Apr [cited 2021 Jan 24]. Report No.: NCT02430792. Available 1049 from: https://clinicaltrials.gov/ct2/show/NCT02430792

- 1050 74. Cramer H. Hatha Yoga for Patients With Colorectal Cancer a Randomized Controlled Trial
 1051 [Internet]. clinicaltrials.gov; 2012 Aug [cited 2021 Jan 24]. Report No.: NCT01669109. Available
 1052 from: https://clinicaltrials.gov/ct2/show/NCT01669109
- 105375. Velthuis M. Physical Activity during Cancer Treatment study (PACT) [Internet]. Netherlands Trial1054Register; 2009 Dec [cited 2021 Jan 25]. Available from: https://www.trialregister.nl/trial/2021
- T6. Das S, Mitra K, Mandal M. Sample size calculation: Basic principles. Indian J Anaesth. 2016
 Sep;60(9):652–6.
- 1057 77. Chen T, Li C, Qin R, Wang Y, Yu D, Dodd J, et al. Comparison of Clinical Trial Changes in Primary
 1058 Outcome and Reported Intervention Effect Size Between Trial Registration and Publication.
 1059 JAMA Netw Open. 2019 Jul 3;2(7):e197242–e197242.
- Schmitz KH, Troxel AB, Dean LT, DeMichele A, Brown JC, Sturgeon K, et al. Effect of Home-Based
 Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among
 Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial. JAMA Oncol.
 2019 Aug;5(11):1605–13.
- 1064 79. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to
 1065 statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009 Jan
 1066 21;(1):MR000006.
- 1067 80. Altman DG, Moher D, Schulz KF. Harms of outcome switching in reports of randomised trials:
 1068 CONSORT perspective. BMJ. 2017 Feb 14;356:j396.
- 1069 81. Furzer B. A randomised controlled trial assessing the efficacy of exercise versus a
 1070 complementary therapy on physical and psychosocial outcomes in lymphoma and myeloma
 1071 patients post chemotherapy (THRIVING) [Internet]. Australian New Zealand Clinical Trials
 1072 Registry; 2009 Dec [cited 2021 Jan 26]. Available from:
- 1073https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83955&showOriginal=true&i1074sReview=true
- 1075 82. Schmitz KH, Campbell AM, Stuiver MM, Pinto BM, Schwartz AL, Morris GS, et al. Exercise is
 1076 medicine in oncology: Engaging clinicians to help patients move through cancer. CA Cancer J Clin
 1077 [Internet]. [cited 2019 Oct 29];0(0). Available from:
- 1078 https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21579
- 1079 83. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc
 1080 Sci Med 1982. 2018 Aug;210:2–21.
- 1081 84. Akobeng AK. Understanding randomised controlled trials. Arch Dis Child. 2005 Aug 1;90(8):840–
 1082 4.
- 1083 85. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane
 1084 Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343(oct18
 1085 2):d5928–d5928.
- 1086 86. Patel AV, Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al. American College
 1087 of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer
 1088 Prevention and Control. Med Sci Sports Exerc. 2019 Nov;51(11):2391–402.

- 1089 87. Hayes SC, Newton RU, Spence RR, Galvão DA. The Exercise and Sports Science Australia position
 1090 statement: Exercise medicine in cancer management. J Sci Med Sport. 2019 Nov;22(11):1175–
 1091 99.
- 1092 88. Lakens D. The Value of Preregistration for Psychological Science: A Conceptual Analysis
 1093 [Internet]. PsyArXiv; 2019 Nov [cited 2020 Nov 15]. Available from: https://psyarxiv.com/jbh4w/
- 1094 89. Collaboration OS. Estimating the reproducibility of psychological science. Science. 2015 Aug
 1095 28;349(6251):aac4716.
- 1096 90. Munafò MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, Percie du Sert N, et al. A
 1097 manifesto for reproducible science. Nat Hum Behav. 2017 Jan 10;1(1):1–9.
- 1098 91. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. Proc Natl Acad
 1099 Sci U S A. 2018 13;115(11):2600–6.
- 1100 92. Mayo DG. Statistical inference as severe testing: how to get beyond the statistics wars.1101 Cambridge: Cambridge University Press; 2018.
- 1102 93. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
 1103 explanation and elaboration: guidance for protocols of clinical trials. BMJ [Internet]. 2013 Jan 9
 1104 [cited 2020 Nov 15];346. Available from: https://www.bmj.com/content/346/bmj.e7586
- 94. Chambers CD, Dienes Z, McIntosh RD, Rotshtein P, Willmes K. Registered reports: realigning
 incentives in scientific publishing. Cortex. 2015;66:A1-2.
- 1107 95. Caldwell AR, Vigotsky AD, Tenan MS, Radel R, Mellor DT, Kreutzer A, et al. Moving sport and
 1108 exercise science forward: a call for the adoption of more transparent research practices. Sports
 1109 Med. 2020;50(3):449–59.

1110